別品名 |
Methazolastone, Temodal, Temodar, 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5- tetrazine-8-carboxamide
|
別包装 |
あり
|
純度 |
>=98%
|
分子量 |
194.15
|
CAS RN® |
85622-93-1
|
化合物の概要 |
Imidazotetrazine, DNA alkylator.
|
構造 |
C6H6N6O2
|
溶媒 |
Soluble in DMSO to 39mg/mL, Water to 5 mg/mL, Ethanol <1mg/mL
|
使用目的 |
Temozolomide is a second generation imidazotetrazine anticancer chemotherapeutic that is clinically approved to treat gliobastoma multiforme, anaplastic astrocytoma, and oligodendrocytoma. Temozolomide acts as an alkylating agent, attaching alkyl groups to guanine bases in DNA and interfering with DNA replication. This compound is 100% orally bioavailable and enters the cerebrospinal fluid easily and quickly.
|
その他 |
[融点]212℃ (dec)
|
参考文献 |
Nagasawa DT, Chow F, Yew A, et al. Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am. 2012 Apr;23(2):307-22, ix. PMID: 22440874.Wesolowski JR, Rajdev P, Mukherji SK. Temozolomide (Temodar). AJNR Am J Neuroradiol. 2010 Sep;31(8):1383-4. PMID: 2053882.Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000 Jul;6(7):2585-97. PMID: 10914698.Horing E, Harter PN, Seznec J, et al. The ''go or grow'' potential of gliomas is linked to the necropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress. Acta Neuropathol. 2012 Jul;124(1):83-97. PMID: 22249620.Momiyama M, Suetsugu A, Chishima T, et al. Subcellular real-time imaging of the efficacy of temozolomide on cancer cells in the brain of live mice. Anticancer Res. 2013 Jan;33(1):103-106. PMID: 23267133.
|
※サムネイル画像をクリックすると拡大画像が表示されます。
|
|
|
メーカー |
品番 |
包装 |
LKT
|
T1849
|
500 MG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
法規制 |
安
|
保存温度 |
4℃
|
|